We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nova Leap Health Corp | TSXV:NLH | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.025 | 10.00% | 0.275 | 0.25 | 0.275 | 0.275 | 0.275 | 0.275 | 1,000 | 18:00:00 |
At the meeting, the six nominees to the Company’s Board of Directors, Chris Dobbin, Wayne Myles, Michael O’Keefe, Dana Hatfield, Marie Mullally and Anne Whelan, were elected for the ensuing year. Grant Thornton LLP was re-appointed as the Company’s auditor to hold office until the next annual meeting of shareholders or until its successor is duly appointed, at a remuneration to be fixed by the Board.
In addition, the second amended and restated equity incentive plan of the Company (the “Plan”), which amends and restates the Company’s existing amended and restated equity incentive plan, was approved and ratified. The principal amendment was to change the Plan to a 10% “rolling” plan, allowing for the issuance of stock options and deferred share units up to a maximum of 10% of the issued and outstanding common shares of the Company, and removing the fixed maximum number of common shares that may be issued upon redemption of deferred share units. More information on the Plan, including a copy of the Plan, is available in the Company’s Management Information Circular dated May 30, 2023 filed on SEDAR.
The voting results for the annual and special meeting of the shareholders held on June 28, 2023 were as follows:
MOTIONS | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | |||||||||||||
FOR | AGAINST | WITHHELD/ ABSTAIN | SPOILED | NON VOTE | FOR | AGAINST | WITHHELD/ | ||||||||
ABSTAIN | |||||||||||||||
Christopher Dobbin | 40,101,920 | 152,560 | 0 | 0 | 0 | 99.62 | % | 0.38 | % | 0.00 | % | ||||
Dana Hatfield | 40,140,920 | 113,560 | 0 | 0 | 0 | 99.72 | % | 0.28 | % | 0.00 | % | ||||
Michael O'Keefe | 40,167,980 | 86,500 | 0 | 0 | 0 | 99.79 | % | 0.21 | % | 0.00 | % | ||||
Wayne Myles | 40,101,620 | 152,860 | 0 | 0 | 0 | 99.62 | % | 0.38 | % | 0.00 | % | ||||
Marie Mullally | 40,046,420 | 208,060 | 0 | 0 | 0 | 99.48 | % | 0.52 | % | 0.00 | % | ||||
Anne Whelan | 40,046,420 | 208,060 | 0 | 0 | 0 | 99.48 | % | 0.52 | % | 0.00 | % | ||||
Appointment of Auditors | 40,193,980 | - | 60,500 | 0 | 0 | 99.85 | % | 0.00 | % | 0.15 | % | ||||
Approval of Second Amended and Restated Equity Incentive Plan | 39,980,170 | 274,310 | 0 | 0 | 0 | 99.32 | % | 0.68 | % | 0.00 | % |
TOTAL SHAREHOLDERS VOTED BY PROXY: | 64 |
TOTAL SHARES ISSUED & OUTSTANDING: | 86,209,252 |
TOTAL SHARES VOTED: | 40,254,480 |
TOTAL % OF SHARES VOTED: | 46.69% |
About Nova Leap
Nova Leap is an acquisitive home health care services company operating in one of the fastest-growing industries in the U.S. & Canada. The Company performs a vital role within the continuum of care with an individual and family centered focus, particularly those requiring dementia care. Nova Leap achieved the #42 ranking on the 2021 Report on Business ranking of Canada’s Top Growing Companies, the #2 ranking on the 2020 Report on Business ranking of Canada’s Top Growing Companies and the #10 Ranking in the 2019 TSX Venture 50™ in the Clean Technology & Life Sciences sector. The Company is geographically diversified with operations in 10 different U.S. states within the New England, Southeastern, South Central and Midwest regions as well as in Nova Scotia, Canada.
CAUTIONARY STATEMENT:
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information: Chris Dobbin, CPA, ICD.D Director, President and CEO T: 902 401 9480 E:cdobbin@novaleaphealth.com
1 Year Nova Leap Health Chart |
1 Month Nova Leap Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions